| Symbol | SNZZF |
|---|---|
| Name | SENZIME AB |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 753 23 Sweden Verkstadsgatan 8 |
| Telephone | +46 4618515640 |
| Fax | — |
| — | |
| Website | https://senzime.com/ |
| Incorporation | SE |
| Incorporated On | 1999 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | PWC - Uppsala, Sweden; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: NASDAQ Stockholm |
| CIK | 0001674912 |
| Description | Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures Additional info from OTC: |
No news found.